Novartis AG (NYSE:NVS) Receives $141.20 Average Target Price from Analysts

Novartis AG (NYSE:NVS) has been assigned a consensus rating of “Hold” from the sixteen brokerages that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $141.20.

Several equities analysts have recently weighed in on NVS shares. Citigroup reissued a “buy” rating on shares of Novartis in a report on Wednesday. Weiss Ratings downgraded Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research report on Wednesday, April 29th.

Institutional Trading of Novartis

A number of hedge funds have recently bought and sold shares of NVS. Evolution Wealth Management Inc. boosted its position in shares of Novartis by 552.0% during the 2nd quarter. Evolution Wealth Management Inc. now owns 163 shares of the company’s stock valued at $26,000 after acquiring an additional 138 shares during the last quarter. Atlatl Advisers LLC acquired a new position in Novartis during the second quarter worth about $26,000. Archer Investment Corp boosted its position in shares of Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after acquiring an additional 80 shares during the last quarter. Arlington Trust Co LLC purchased a new position in Novartis during the fourth quarter worth approximately $25,000. Finally, CrossGen Wealth LLC purchased a new position in shares of Novartis during the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Price Performance

Shares of NYSE NVS opened at $154.84 on Friday. The stock’s 50 day moving average price is $151.95 and its 200-day moving average price is $152.23. The company has a market capitalization of $295.46 billion, a PE ratio of 23.35, a PEG ratio of 2.68 and a beta of 0.45. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. Novartis has a twelve month low of $112.34 and a twelve month high of $170.46.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion during the quarter. On average, equities analysts anticipate that Novartis will post 8.77 EPS for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.